top of page
Search

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys

New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value



PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company’s first investment in externally developed technology, which it believes will provide significant additional shareholder value and serve as a prudent use for its approximately $74.6 million cash position as of July 31, 2023, which was previously reported in the Company’s Quarterly Report on Form 10-Q filed on September 18, 2023. As part of the agreement, PharmaCyte’s interim CEO Josh Silverman will join the Femasys’ Board of Directors.

“This collaboration with PharmaCyte will support the active commercialization and continued development of our novel reproductive solutions, and Josh’s addition to our Board of Directors will provide much-desired insight on the capital markets as we continue to grow as a publicly traded company” Post this

“The stake we have taken in Femasys is the beginning of an expansion of our corporate strategy that seeks to identify opportunities outside of our own drug development activities where we can create value both through cash investment and our own expertise. Femasys has an impressive track record in product development and commercialization, and its offerings address significant unmet medical needs in the women’s health arena. We believe we can contribute to its continued development and look forward to further collaboration and sharing in Femasys’ success. Further, we will continue to seek out opportunities where the strategic deployment of cash will ultimately result in additional value for PharmaCyte and its shareholders,” said Mr. Silverman.''


Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide. The company is developing a broad portfolio of in-office, accessible solutions, including a late-clinical stage product candidate and FDA-cleared, innovative therapeutic and diagnostic products. Femasys’ FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. Femasys’ FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is now FDA-cleared and has received regulatory approval in Canada. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, and other non-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. The Company’s diagnostic products include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com.


“This collaboration with PharmaCyte will support the active commercialization and continued development of our novel reproductive solutions, and Josh’s addition to our Board of Directors will provide much-desired insight on the capital markets as we continue to grow as a publicly traded company,” said Kathy Lee-Sepsick, founder, president, and chief executive officer of Femasys.


About PharmaCyte Biotech

PharmaCyte is a biotechnology company that is currently evaluating its signature live-cell encapsulation technology, Cell-in-a-Box®, for potential development of cellular therapies for cancer, diabetes, and malignant ascites, while also exploring the opportunity for other strategic acquisitions.


The Cell-in-a Box technology involves encapsulating genetically engineered human cells that can then be reintroduced to attack disease. The Company is exploring possible utility in cancer (particularly pancreatic), Type 1 and insulin-dependent Type 2 diabetes, and malignant ascites.


However, until the review by the Business Review Committee and the Board is complete and the Board has determined the actions and plans to be implemented, the Board has curtailed spending on the foregoing programs.


__________________________________________

Does your company have business or financial objectives?



If your company has business or financial objectives, check out the advisory services for growing global technology companies provided by FC Global Strategies.


FC Global Strategies also sponsors Medical and Pharma Insider and its AI Connect Marketing Program.


Our calendar link to schedule a call.


Contact Us:


Jeffrey Friedland - Based in the U.S.

(North America and Global)

+1 646 450 8909


Ross Swan -Based in Singapore

(Southeast Asia, Australia, Asia-Pacific)

+65 9181 9472

ross@fcglobalstrategies.com


David Krutonog - Based in Israel

(Eastern Europe, Middle-East and North Africa)

+972 50 974 342

david@fcglobalstrategies.com


Claudio Hebling - Based in Brazil

(Latin America)

+55 19 99377 7482

claudio@fcglobalstrategies.com


Vincent Paul Joseph - Based in India

(South Asia, India, Sri Lanka)

+91 962 620 9090

vincent@fcglobalstrategies.com






Comments


Commenting has been turned off.
bottom of page